Persistence and healthcare utilization associated with the use of buprenorphine/naloxone film and tablet formulation therapy in adults with opioid dependence

Journal of Medical Economics

Volumn 17, Issue 9, 2014, Pages 626-636

  Clay, Emilie ^a   Khemiri, Amine ^a   Zah, Vladimir ^b   Aballéa, Samuel ^a   Ruby, Jane ^c   Asche, Carl V ^d  

^a CREATIV CEUTICAL   (France)

^b ZRX OUTCOMES RESEARCH INC   (Canada)

^c RECKITT BENCKISER   (United Kingdom)

^d UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Buprenorphine naloxone; Healthcare utilization; Opioid dependence; Patient persistence

Indexed keywords

BUPRENORPHINE PLUS NALOXONE; BUPRENORPHINE; DRUG COMBINATION; NALOXONE; NARCOTIC ANTAGONIST; TABLET;

ADULT; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; DATA BASE; FEMALE; HAZARD RATIO; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH HAZARD; HOSPITAL ADMISSION; HOSPITAL DEPARTMENT; HUMAN; ICD-9; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MONOTHERAPY; OPIATE ADDICTION; OUTCOME ASSESSMENT; OUTPATIENT; PRESCRIPTION; PRIVATE HEALTH INSURANCE; RETROSPECTIVE STUDY; TABLET FORMULATION; TIME TO TREATMENT; COMORBIDITY; DRUG COMBINATION; HEALTH SERVICE; INSURANCE; MIDDLE AGED; OPIOID-RELATED DISORDERS; STATISTICS AND NUMERICAL DATA; TABLET; UTILIZATION;

ADULT; BUPRENORPHINE; COMORBIDITY; DRUG COMBINATIONS; FEMALE; HEALTH SERVICES; HUMANS; INSURANCE CLAIM REVIEW; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; RETROSPECTIVE STUDIES; TABLETS;

EID: 84906533617     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2014.925463     Document Type: Article

References (22)

1. World Health Organisation. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva, Switzerland, 2009, http://www.who.int/substance-abuse/publications/opioid-dependence-guidelines. pdf. Accessed 28 May 2014
2. Nicholls L, Bragaw L, Ruetsch C. Opioid dependence treatment and guidelines. J Manag Care Pharm 2010;16(1 Suppl B):S14-21. http://www.amcp. org/data/jmcp/S14-S21.pdf. Accessed 28 May 2014
3. Stoops WW, Hatton KW, Lofwall MR, et al. Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: Abuse potential and relative potencies. Psychopharmacology (Berl) 2010;212:193-203
4. Ling W, Mooney L, Hillhouse M. Prescription opioid abuse, pain and addiction: Clinical issues and implications. Drug Alcohol Rev 2011;30:300-5
5. Chandwani HS, Strassels SA, Rascati KL, et al. Estimates of charges associated with emergency department and hospital inpatient care for opioid abuse-related events. J Pain Palliat Care Pharmacother 2013;27:206-13
6. Clark HW. Office-based practice and opioid-use disorders. N Engl J Med 2003;349:928-30
7. Otiashvili D, Piralishvili G, Sikharulidze Z, et al. Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior-Outcomes of a randomized trial. Drug Alcohol Depend 2013;133:376-82
8. Yokell MA, Zaller ND, Green TC, et al. Buprenorphine and buprenorphine/ naloxone diversion, misuse, and illicit use: An international review. Curr Drug Abuse Rev 2011;4:28-41
9. McLellan AT, Lewis DC, O"Brien CP, et al. Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation. JAMA 2000;284:1689-95
10. Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: A 2-phase randomized controlled trial. Arch Gen Psychiatry 2011;68:1238-46
11. Cornish R, Macleod J, Strang J, et al. Risk of death during and after opiate substitution treatment in primary care: Prospective observational study in UK General Practice Research Database. BMJ 2010; 341:c5475
12. Schackman BR, Leff JA, Polsky D, et al. Cost-effectiveness of long-Term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care. J Gen Intern Med 2012;27:669-76
13. Kaur AD, McQueen A, Jan S. Opioid drug utilization and cost outcomes associated with the use of buprenorphine-naloxone in patients with a history of prescription opioid use. J Manag Care Pharm 2008;14:186-94
14. Baser O, Chalk M, Fiellin DA, et al. Cost and utilization outcomes of opioiddependence treatments. Am J Manag Care 2011;17(8 Suppl):S235-48
15. Barnett PG. Comparison of costs and utilization among buprenorphine and methadone patients. Stanford University, CA: Veterans Affairs Health Economics Resource Center and Department of Health Research and Policy, 2013
16. Optum insight, clinformatics Data Mart. http://www.optuminsight.com/ lifesciences/ solutions/value-strategy/marketing-Analytics/clinformatics- datamart/-/media/Ingenix/Life-Sciences/Documents/OptumInsightLifeSciences ClinformaticsDataMart-old.pdf. Accessed 24 May 2014
17. The National Center for Health Statistics (NCHS) and the Centers for Medicare and Medicaid Services. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). http://www.cdc.gov/nchs/icd/ icd9cm.htm. Accessed 28 May 2014
18. Medicare Fee-for-service. http://www.cms.gov/Medicare/Coding/ICD10/ Medicare-Fee-for-Service-Provider-Resources.html. Accessed 28 May 2014
19. First Databank. http://www.fdbhealth.com/. Accessed 28 May 2014
20. SAS Institute Inc. SAS V9.3. Cary, NC: SAS Institute Inc, http://support. sas.com/software/93/. Accessed 28 May 2014
21. Strain EC, Stitzer ML, Liebson IA, et al. Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users. Psychopharmacology (Berl) 1994;116:401-6
22. Zah V, Clay E, Aballea S, et al. Patient persistence with Buprenorphine/ Naloxone Film and tablet formulations in the treatment of opioid dependence in the United States: Results from a privately insured retrospective database, Association for Medical Education and Research in Substance Abuse, 36th Annual National Conference, Bethesda, Maryland, 2012